XORTX THERAPEUTICS INC (XRTX) Fundamental Analysis & Valuation

NASDAQ:XRTX • CA98420Q3061

0.468 USD
+0.01 (+1.76%)
At close: Mar 10, 2026
0.435 USD
-0.03 (-7.05%)
After Hours: 3/10/2026, 8:00:03 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This XRTX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

1

Taking everything into account, XRTX scores 1 out of 10 in our fundamental rating. XRTX was compared to 193 industry peers in the Pharmaceuticals industry. XRTX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. XRTX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. XRTX Profitability Analysis

1.1 Basic Checks

  • In the past year XRTX has reported negative net income.
  • In the past year XRTX has reported a negative cash flow from operations.
  • XRTX had negative earnings in each of the past 5 years.
  • XRTX had a negative operating cash flow in each of the past 5 years.
XRTX Yearly Net Income VS EBIT VS OCF VS FCFXRTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -69.13%, XRTX is doing worse than 72.02% of the companies in the same industry.
  • With a Return On Equity value of -98.46%, XRTX is not doing good in the industry: 64.77% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -69.13%
ROE -98.46%
ROIC N/A
ROA(3y)-60.92%
ROA(5y)-49.27%
ROE(3y)-85.37%
ROE(5y)-73.65%
ROIC(3y)N/A
ROIC(5y)N/A
XRTX Yearly ROA, ROE, ROICXRTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K

1.3 Margins

  • XRTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XRTX Yearly Profit, Operating, Gross MarginsXRTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. XRTX Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for XRTX has been increased compared to 1 year ago.
  • XRTX has less shares outstanding than it did 5 years ago.
  • XRTX has a worse debt/assets ratio than last year.
XRTX Yearly Shares OutstandingXRTX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M
XRTX Yearly Total Debt VS Total AssetsXRTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

  • XRTX has an Altman-Z score of -9.99. This is a bad value and indicates that XRTX is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of XRTX (-9.99) is worse than 68.91% of its industry peers.
  • There is no outstanding debt for XRTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -9.99
ROIC/WACCN/A
WACCN/A
XRTX Yearly LT Debt VS Equity VS FCFXRTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M

2.3 Liquidity

  • XRTX has a Current Ratio of 1.62. This is a normal value and indicates that XRTX is financially healthy and should not expect problems in meeting its short term obligations.
  • XRTX has a Current ratio of 1.62. This is in the lower half of the industry: XRTX underperforms 66.84% of its industry peers.
  • A Quick Ratio of 1.62 indicates that XRTX should not have too much problems paying its short term obligations.
  • XRTX has a Quick ratio (1.62) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 1.62
Quick Ratio 1.62
XRTX Yearly Current Assets VS Current LiabilitesXRTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. XRTX Growth Analysis

3.1 Past

  • The earnings per share for XRTX have decreased strongly by -1213.33% in the last year.
EPS 1Y (TTM)-1213.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.88%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-11.64%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
XRTX Yearly EPS VS EstimatesXRTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 -2 -4 -6 -8

More info and screens

Find the best growth stocksShow best growing peers

0

4. XRTX Valuation Analysis

4.1 Price/Earnings Ratio

  • XRTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year XRTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XRTX Price Earnings VS Forward Price EarningsXRTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XRTX Per share dataXRTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. XRTX Dividend Analysis

5.1 Amount

  • XRTX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

XRTX Fundamentals: All Metrics, Ratios and Statistics

XORTX THERAPEUTICS INC

NASDAQ:XRTX (3/10/2026, 8:00:03 PM)

After market: 0.435 -0.03 (-7.05%)

0.468

+0.01 (+1.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-14
Earnings (Next)03-30
Inst Owners3.31%
Inst Owner Change128.38%
Ins Owners1.91%
Ins Owner ChangeN/A
Market Cap3.26M
Revenue(TTM)N/A
Net Income(TTM)-1.94M
Analysts80
Price TargetN/A
Short Float %1.72%
Short Ratio0.65
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.65
P/tB 1.83
EV/EBITDA N/A
EPS(TTM)-0.47
EYN/A
EPS(NY)-1.55
Fwd EYN/A
FCF(TTM)-0.43
FCFYN/A
OCF(TTM)-0.42
OCFYN/A
SpS0
BVpS0.28
TBVpS0.26
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -69.13%
ROE -98.46%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-60.92%
ROA(5y)-49.27%
ROE(3y)-85.37%
ROE(5y)-73.65%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 31.78%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.62
Quick Ratio 1.62
Altman-Z -9.99
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)48.3%
Cap/Depr(5y)87.61%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1213.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.88%
EPS Next Y-11.64%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y27.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-29.82%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y67.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y67.46%
OCF growth 3YN/A
OCF growth 5YN/A

XORTX THERAPEUTICS INC / XRTX FAQ

What is the ChartMill fundamental rating of XORTX THERAPEUTICS INC (XRTX) stock?

ChartMill assigns a fundamental rating of 1 / 10 to XRTX.


What is the valuation status of XORTX THERAPEUTICS INC (XRTX) stock?

ChartMill assigns a valuation rating of 0 / 10 to XORTX THERAPEUTICS INC (XRTX). This can be considered as Overvalued.


Can you provide the profitability details for XORTX THERAPEUTICS INC?

XORTX THERAPEUTICS INC (XRTX) has a profitability rating of 0 / 10.


What is the financial health of XORTX THERAPEUTICS INC (XRTX) stock?

The financial health rating of XORTX THERAPEUTICS INC (XRTX) is 5 / 10.


What is the earnings growth outlook for XORTX THERAPEUTICS INC?

The Earnings per Share (EPS) of XORTX THERAPEUTICS INC (XRTX) is expected to decline by -11.64% in the next year.